Effect of CYP3A5 and MDR1 gene polymorphism on concentration/dose ratios of tacrolimus in Chinese liver transplant patients

Chinese Pharmaceutical Journal

Volumn 43, Issue 9, 2008, Pages 649-653

  Jin, Zhao ^a   Zhang, Wei Xia ^a   Chen, Bing ^a   Mao, An Wei ^a   Chen, Hao ^a   Gu, Zhi Dong ^a   Cai, Wei Min ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

CYP3A5; Liver transplantation; MDR1; Polymorphism; Tacrolimus

Indexed keywords

CYTOCHROME P450 3A5; MULTIDRUG RESISTANCE PROTEIN 1; TACROLIMUS;

ARTICLE; CHINESE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG BLOOD LEVEL; GENOTYPE; HUMAN; LIVER GRAFT;

EID: 52749090246     PISSN: 10012494     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. HUANG W, LIN Y S, MCCONN D J, et al. Evidence of significant contribution from CYP3A5 to hepatic drug metabolism[J]. Drug Metab Dispos, 2004, 32(12):1434-1445.
2. KAMDEM L K, STREIT F, ZANGER U M, et al. Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus[J]. Clini Chem, 2005, 51(8):1374-1381.
3. KIM R B, LEAKE B F, CHOO E F, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans[J]. Clin Pharmacol Ther, 2001, 70(2): 189-199.
4. SAKAEDA T, NAKAMURA T, OKUMURA K. Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs[J]. Pharmacogenomics, 2003, 4(4): 397-410.
5. HOFFMEYER S, BURK O, VON RICHTER O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo[J]. Proc Natl Acad Sci USA, 2000, 97(7):3473-3478.
6. HU Y F, HE J, CHEN G L, et al. CYP3A5 * 3 and CYP3A4 * 18 single nucleotide polymorphisms in a Chinese population[J]. Clini Chim Acta, 2005, 353(1-2):187-192.
7. VENKATARAMANAN R, SWAMINATHAN A, PRASAD T, et al. Clinical pharmacokinetics of tacrolimus[J]. Clin Pharmacokinet, 1995, 29(6):404-430.
8. WALLEMACQ P E, VERBEEDK R K. Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients[J]. Clin Pharmacokinet, 2001, 40(4):283-295.
9. MANCINELLI L M, FRASSETTO L, FLOREN L C, et al. The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups[J]. Clin Pharmacol Ther, 2001, 69 (1):24-31.
10. KUEHL P, ZHANG J, LIN Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression[J]. Nat Genet, 2001, 27(4): 383-391.
11. SIMPSON D, NOBLE S. Tacrolimus ointment: a review of its use in atopic dermatitis and its clinical potential in other inflammatory skin conditions[J]. Drugs, 2005, 65(6):827-858.
12. ZHENG H, ZEEVI A, SCHUETZ E, et al. Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism[J]. J Clin Pharmacol, 2004, 44(2):135-140.
13. ZHANG X, LIU Z, ZHENG J M, et al. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation[J]. Clin Transplant, 2005, 19(5):638-643.
14. ZHENG H, WEBBER S, ZEEVI A, et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms[J]. Am J Transplant, 2003,3(4): 477-483.
15. FUKUDO M, YANO I, MASUDA S, et al. Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients[J]. Clin Pharmacol Ther, 2006, 80(4):331-345.
16. GOTO M, MASUDA S, KIUCHI T, et al. CYP3A5 * 1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation[J]. Pharmacogenetics, 2004, 14(7):471-478.
17. UESUGI M, MASUDA S, KATSURA T, et al. Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients[J]. Pharmacogenet Genomics, 2006, 16(2):119-127.
18. YU S F, WU L H, JIN J, et al. Influence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation[7J]. Transplantation, 2006, 81(1):46-51.
19. WANG W L, JIN J, ZHENG S S, et al. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients[J]. Liver Transplantation, 2006, 12(5):775-780.
20. MASUDA S, GOTO M, OKUDA M, et al. Initial dosage adjustment for oral administration of tacrolimus using the intestinal MDR1 level in living-donor liver transplant recipients[J]. Transplant Proc, 2005, 37(4):1728-1729.